NCT02579226View on ClinicalTrials.gov

A Phase I Study of Safety, Tolerability, and PK of AZD2811 in Patients With Advanced Solid Tumors.

PHASE1CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

October 28, 2015

Primary Completion Date

February 7, 2020

Study Completion Date

April 3, 2020

Conditions
Advanced Solid Tumours
Interventions
DRUG

AZD2811

The study will be conducted in 2 parts, dose-escalation (A) and dose-expansion (B). All patients in both parts of the study with receive AZD2811.

Trial Locations (6)

34232

Research Site, Sarasota

37203

Research Site, Nashville

53226

Research Site, Milwaukee

77030

Research Site, Houston

80218

Research Site, Denver

02215

Research Site, Boston

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY